SCOTTSDALE, AZ--(Marketwire - May 22, 2008) - Medistem Laboratories, Inc. (OTCBB: MDSM) and Orcrist Bio Inc. (ORC) announced today that the companies have entered a collaborative agreement to co-develop therapies based upon their respective core intellectual properties. This includes utilization of Medistem’s newly discovered Endometrial Regenerative Cell population and ORC’s recently licensed HYC750 technology.
